Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-64509-5
Affiliations:
4
Authors:
13
Go to article
Institutions Authors Share
NIH NCI Center for Cancer Research (CCR), United States of America (USA)
11.000000
11.000000
 0.85
AstraZeneca Cambridge, United Kingdom (UK)
2.000000
 0.15
Interested in Oncology and Carcinogenesis?